Oculis announces Phase 2 data for topical drops to treat dry eye disease - Ophthalmology Times
8/23/2022 12:00:00 AM3 years 6 months ago
by David Hutton, OT Staff Reports
by David Hutton, OT Staff Reports
According to the company, topical eye drops anti-TNFα agent licaminlimab (OCS-02) relieve persistent ocular discomfort in severe dry eye disease.
Oculis S.A., today announced results of the double blinded, multicenter and placebo controlled Phase 2 clinical trial assessing the effect of topical licaminlimab (OCS-02) on global ocular discomfort… [+4505 chars]
full article...